Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6

被引:113
作者
Gong, Yuhua [1 ]
Mao, Jinzhong [2 ]
Wu, Di [3 ]
Wang, Xuemei [1 ]
Li, Long [1 ]
Zhu, Liang [1 ]
Song, Rong [1 ]
机构
[1] Third Peoples Hosp Zhenjiang, Dept Clin Lab, 300 Daijiamen, Zhenjiang 212005, Jiangsu, Peoples R China
[2] Third Peoples Hosp Zhenjiang, Dept Radiol, 300 Daijiamen, Zhenjiang 212005, Jiangsu, Peoples R China
[3] Third Peoples Hosp Zhenjiang, Dept Hepatosis Inpatient, 300 Daijiamen, Zhenjiang 212005, Jiangsu, Peoples R China
关键词
Circ-ZEB133; miR-200a-3p; CDK6; HCC; CDK4/6; INHIBITORS; BREAST-CANCER; CELL-CYCLE; KINASE; THERAPEUTICS;
D O I
10.1186/s12935-018-0602-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Accumulating data indicated that circRNA plays important roles in regulating many biological processes of the tumor, the present study is designated for exploring roles of the circ-ZEB1.33-miR-200a-3p-CDK6 regulating axis in human hepatocellular carcinoma (HCC). Methods: The regulation axis as predicted by using online tool circNet, the expression and correlation of circZEB1.33-miR-200a-3p-CDK6 was verified in human HCC. The diagnostic value of both tumor and serum circ-ZEB1.33 was estimated by using clinical samples. The roles of circ-ZEB1.33-miR-200a-3p-CDK6 in regulating cell cycle were explored by using in vitro studies. Results: Overexpression of circ-ZEB1.33 and CDK6, downregulation of miR-200a-3p were detected in human HCC tissues, negative correlation between circ-ZEB1.33 and miR-200a-3p, positive correlation between circ-ZEB1.33 and CDK6 were confirmed in human HCC tissues. Tissue and serum circ-ZEB1.33 were related to different TMN stages and prognosis in HCC patients. RNA pull-down assay implied that circ-ZEB1.33 could decrease miR-200a-3p by sponging miR-200a-3p, and the luciferase reporter assay indicated that miR-200a-3p could downregulate CDK6 transcription by targeting its 3'UTR. The in vitro assays indicated that circ-ZEB1.33 could promote the proliferation of HCC cells by increasing the percentage of S phase regulated by CDK6/Rb. Conclusion: Proliferation promotion roles of the circ-ZEB1.33-miR-200a-3p-CDK6 regulating axis are existed and verified in human HCC, both tumor and serum circ-ZEB1.33 can serve as an indicator for the prognosis of HCC patients.
引用
收藏
页数:9
相关论文
共 16 条
[1]
Racing to block tumorigenesis after pRb loss An innocuous point mutation wins with synthetic lethality [J].
Bauzon, Frederick ;
Zhu, Liang .
CELL CYCLE, 2010, 9 (11) :2118-2123
[2]
MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma [J].
Bustos, Matias A. ;
Ono, Shigeshi ;
Marzese, Diego M. ;
Oyama, Takashi ;
Iida, Yuuki ;
Cheung, Garrett ;
Nelson, Nellie ;
Hsu, Sandy C. ;
Yu, Qiang ;
Hoon, Dave S. B. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (09) :1955-1964
[3]
Co-Expression of XIAP and Cyclin D1 Complex Correlates with a Poor Prognosis in Patients with Hepatocellular Carcinoma [J].
Che, Yufang ;
Ye, Fei ;
Xu, Ruliang ;
Qing, Haitao ;
Wang, Xinying ;
Yin, Fei ;
Cui, Miao ;
Burstein, David ;
Jiang, Bo ;
Zhang, David Y. .
AMERICAN JOURNAL OF PATHOLOGY, 2012, 180 (05) :1798-1807
[4]
Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future [J].
DiPippo, Adam J. ;
Patel, Neelam K. ;
Barnett, Chad M. .
PHARMACOTHERAPY, 2016, 36 (06) :652-667
[5]
Competitive endogenous RNA in colorectal cancer: A systematic review [J].
Han Shuwen ;
Zhou Qing ;
Zheng Yan ;
Yang Xi .
GENE, 2018, 645 :157-162
[6]
Cell-Cycle Therapeutics Come of Age [J].
Ingham, Matthew ;
Schwartz, Gary K. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (25) :2949-+
[7]
Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers? [J].
Kalu, Nene N. ;
Johnson, Faye M. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (02) :207-217
[8]
Circular RNAs in cancer: opportunities and challenges in the field [J].
Kristensen, L. S. ;
Hansen, T. B. ;
Veno, M. T. ;
Kjems, J. .
ONCOGENE, 2018, 37 (05) :555-565
[9]
CircNet: a database of circular RNAs derived from transcriptome sequencing data [J].
Liu, Yu-Chen ;
Li, Jian-Rong ;
Sun, Chuan-Hu ;
Andrews, Erik ;
Chao, Rou-Fang ;
Lin, Feng-Mao ;
Weng, Shun-Long ;
Hsu, Sheng-Da ;
Huang, Chieh-Chen ;
Cheng, Chao ;
Liu, Chun-Chi ;
Huang, Hsien-Da .
NUCLEIC ACIDS RESEARCH, 2016, 44 (D1) :D209-D215
[10]
Treating cancer with selective CDK4/6 inhibitors [J].
O'Leary, Ben ;
Finn, Richard S. ;
Turner, Nicholas C. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (07) :417-430